{"title":"Review of nano technology of Covid 19 vaccines","authors":"Mohamed Ashraf","doi":"10.21608/ASAJS.2021.159448","DOIUrl":null,"url":null,"abstract":"103 3 Review of nano technology of Covid 19 vaccines BY Mohamed Ashraf Mohamed, M.A.M., Pharmaceutics department, Egyptian Russian University, ERU Doi: 10.21608/asajs.2021.159448 : ثحبلا ملاتسا 3 / 3 / 2021 : رشنلا لوبق 25 / 3 / 2021 ـــــــــــــــــــــــــــــــــــــــــ ـــــــــــــــــــــ ــــــــــــــــــــــــــــــــــــــــــــــــــــــ Introduction : The global current situation, no return to pre-Covid 19 social pattern unless development of safe preventive vaccines. Fortunately, in the last few months since identity of SARS CoV-2more than two hundred academic laboratories &companies initiated vaccine development, and many are making record time in advancing to clinical trials (Pene, et.al., (2003).","PeriodicalId":209738,"journal":{"name":"المجلة العربیة للعلوم الزراعیة","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"المجلة العربیة للعلوم الزراعیة","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/ASAJS.2021.159448","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
103 3 Review of nano technology of Covid 19 vaccines BY Mohamed Ashraf Mohamed, M.A.M., Pharmaceutics department, Egyptian Russian University, ERU Doi: 10.21608/asajs.2021.159448 : ثحبلا ملاتسا 3 / 3 / 2021 : رشنلا لوبق 25 / 3 / 2021 ـــــــــــــــــــــــــــــــــــــــــ ـــــــــــــــــــــ ــــــــــــــــــــــــــــــــــــــــــــــــــــــ Introduction : The global current situation, no return to pre-Covid 19 social pattern unless development of safe preventive vaccines. Fortunately, in the last few months since identity of SARS CoV-2more than two hundred academic laboratories &companies initiated vaccine development, and many are making record time in advancing to clinical trials (Pene, et.al., (2003).